Literature DB >> 9850038

CD20-negative relapse in B-cell lymphoma after treatment with Rituximab.

T Kinoshita, H Nagai, T Murate, H Saito.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9850038

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  13 in total

1.  Epigenetic regulation of CD20 protein expression in a novel B-cell lymphoma cell line, RRBL1, established from a patient treated repeatedly with rituximab-containing chemotherapy.

Authors:  Akihiro Tomita; Junji Hiraga; Hitoshi Kiyoi; Manabu Ninomiya; Takumi Sugimoto; Masafumi Ito; Tomohiro Kinoshita; Tomoki Naoe
Journal:  Int J Hematol       Date:  2007-07       Impact factor: 2.490

2.  Establishment of a novel CD20 negative mature B-cell line, WILL2, from a CD20 positive diffuse large B-cell lymphoma patient treated with rituximab.

Authors:  Takashi Sonoki; Yaqiong Li; Setsuko Miyanishi; Hirokazu Nakamine; Nobuyoshi Hanaoka; Hiroshi Matsuoka; Ichiro Mori; Hideki Nakakuma
Journal:  Int J Hematol       Date:  2009-03-31       Impact factor: 2.490

3.  Prenyltransferases regulate CD20 protein levels and influence anti-CD20 monoclonal antibody-mediated activation of complement-dependent cytotoxicity.

Authors:  Magdalena Winiarska; Dominika Nowis; Jacek Bil; Eliza Glodkowska-Mrowka; Angelika Muchowicz; Malgorzata Wanczyk; Kamil Bojarczuk; Michal Dwojak; Malgorzata Firczuk; Ewa Wilczek; Malgorzata Wachowska; Katarzyna Roszczenko; Marta Miaczynska; Justyna Chlebowska; Grzegorz Wladyslaw Basak; Jakub Golab
Journal:  J Biol Chem       Date:  2012-07-26       Impact factor: 5.157

Review 4.  Rituximab.

Authors:  S V Onrust; H M Lamb; J A Balfour
Journal:  Drugs       Date:  1999-07       Impact factor: 9.546

Review 5.  Loss of CD20 antigen expression after rituximab therapy of CD20 positive B cell lymphoma (diffuse large B cell extranodal marginal zone lymphoma combination): a case report and review of the literature.

Authors:  Berna Bozkurt Duman; Berksoy Sahin; Melek Ergin; Birol Guvenc
Journal:  Med Oncol       Date:  2011-07-31       Impact factor: 3.064

Review 6.  Lymphoproliferative disorders after solid organ transplantation-classification, incidence, risk factors, early detection and treatment options.

Authors:  Gyula Végso; Melinda Hajdu; Anna Sebestyén
Journal:  Pathol Oncol Res       Date:  2010-12-31       Impact factor: 3.201

7.  Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis.

Authors:  Catherine M Shachaf; Omar D Perez; Sawsan Youssef; Alice C Fan; Sailaja Elchuri; Matthew J Goldstein; Amy E Shirer; Orr Sharpe; Joy Chen; Dennis J Mitchell; Maria Chang; Garry P Nolan; Lawrence Steinman; Dean W Felsher
Journal:  Blood       Date:  2007-07-10       Impact factor: 22.113

8.  Existence of leukemic clones resistant to both imatinib mesylate and rituximab before drug therapies in a patient with Philadelphia chromosome-positive acute lymphocytic leukemia.

Authors:  Takaaki Hato; Jun Yamanouchi; Tatsushiro Tamura; Norimasa Hojo; Yasunari Niiya; Masashi Kohno; Shiro Bando; Yoshihiro Yakushijin; Kiyonori Takada; Ikuya Sakai; Masaki Yasukawa; Shigeru Fujita
Journal:  Int J Hematol       Date:  2004-07       Impact factor: 2.490

9.  Re-treatment of relapsed indolent B-cell lymphoma with rituximab.

Authors:  T Igarashi; T Ohtsu; H Fujii; Y Sasaki; Y Morishima; M Ogura; Y Kagami; T Kinoshita; M Kasai; Y Kiyama; Y Kobayashi; K Tobinai
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.319

Review 10.  Monoclonal antibody therapy for B-cell lymphoma: clinical trials of an anti-CD20 monoclonal antibody for B-cell lymphoma in Japan.

Authors:  Kensei Tobinai
Journal:  Int J Hematol       Date:  2002-12       Impact factor: 2.319
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.